Terns Pharmaceuticals (TERN – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...

William Blair initiated coverage of Terns Pharmaceuticals (TERN) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports.

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday ...

Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additional ...